文献速递免疫规划卫生政策与健康促进

三价重组流感疫苗上市后安全性监测:向疫苗不良事件报告系统的报告

Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
PubMed 文献 · Vaccine · 2017-09-05

2013年1月16日美国批准首个完全无鸡蛋的流感疫苗RIV3(Flublok)。截至2016年6月30日,VAERS收到88份RIV3接种后报告,过敏反应最常见,其中10例符合Brighton协作组过敏反应定义,21份报告描述非过敏反应的过敏反应,11份报告提示超敏反应的体征和症状。

要点

  • 截至2016年6月30日,VAERS收到88份RIV3接种后报告。
  • 过敏反应(含过敏症)是最常见的不良事件类型。
  • 10例符合Brighton协作组过敏症病例定义,21份报告描述非过敏症的过敏反应,11份报告提示超敏反应。

核心结论

  • 部分个体发生过敏症和其他过敏反应可能反映潜在特应性倾向,不一定提示与疫苗产品特有成分存在因果关系。
  • 需进一步研究可能阐明流感疫苗接种后过敏反应的机制,鸡蛋蛋白和流感血凝素可能作用很小或没有作用。
  • 接种疫苗仍是预防流感及其并发症的最佳防御手段。

研究设计与样本

  • 对美国疫苗不良事件报告系统(VAERS)中RIV3接种后报告进行回顾和总结,截至2016年6月30日共收到88份报告。

主要发现

  • 过敏反应包括过敏症是最常见的不良事件类型。
  • 经医学审查,10例符合Brighton协作组过敏症病例定义,21份报告描述非过敏症的过敏反应,11份报告描述提示超敏反应的体征和症状。
  • 其他不良事件包括注射部位反应、疲劳、肌痛、头痛和发热。

临床怎么用

  • 本文总结的信息可能有助于政策制定者、卫生官员、临床医生和患者就疫苗接种策略做出更明智的决定。
  • 接种疫苗仍是预防流感及其并发症的最佳防御手段。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On January 16, 2013, the Food and Drug Administration approved recombinant hemagglutinin influenza vaccine (RIV3) (Spodoptera frugiperda cell line; Flublok), which is the first completely egg-free flu vaccine licensed in the United States. To improve our understanding of the safety profile of this vaccine, we reviewed and summarized reports to the Vaccine Adverse Event Reporting System (VAERS) following RIV3. Through June 30, 2016, VAERS received 88 reports. Allergic reactions, including anaphylaxis, were the most common type of adverse event. Based on medical review, 10 cases met the Brighton Collaboration case definition of anaphylaxis, 21 reports described allergic reactions other than anaphylaxis, and 11 reports described signs and symptoms that suggested hypersensitivity. Other adverse events included injection site reactions, fatigue, myalgia, headache, and fever. The occurrence of anaphylaxis and other allergic reactions in some individuals may reflect an underlying predisposition to atopy that may manifest itself after an exposure to any drug or vaccine, and it does not necessarily suggest a causal relationship with the unique constituents that are specific to the vaccine product administered. Further research may elucidate the mechanism of allergic reactions following influenza vaccination: it is possible that egg proteins and influenza hemagglutinin play little or no role. Vaccination remains the single best defense against influenza and its complications. The information summarized here may enable policy makers, health officials, clinicians, and patients to make a more informed decision regarding vaccination strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Woo EJ, Moro PL, Cano M, et al. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Vaccine. 2017. PMID: 28886946. doi:10.1016/j.vaccine.2017.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。